Investor Presentaiton
Investor Presentation
First nine months of 2018
Slide 34
Million
50
North America Operations at a glance
Diabetes trend in population
Population with diabetes
Diabetes market by value and
Novo Nordisk market share
Diabetes growth rate
NN Insulin MS
NN OAD MS
bDKK
400
Novo Nordisk reported sales
NN GLP-1 MS
First nine months of
2018
Sales
(mDKK) growth²
YTD
80%
40
18%
40
230%
Long-acting insulin³
Premix insulin4
9,455
(9%)
1,061
(16%)
GLP-1
300
60% Fast-acting insulin5
7,389
(9%)
39
38.0%¹
Human insulin
1,485
13%
30
33
200
40%
Total insulin
19,390
(8%)
20
10
20
GLP-16
13,971
18%
18.2%¹
Insulin
100
20%
10
Other diabetes care?
Diabetes care
638
0%
33,999
1%
10
22.3%¹
OAD
Obesity (SaxendaⓇ)
1,825
31%
0
0
0%
Biopharm³
5,234
(8%)
2000
2017
2045
Aug
2013
Aug
2018
Total
41,058
1%
North America Population 2018: ~0.4 billion people and diabetes
prevalence
11%
Source: International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 8th Edition 2017
1 CAGR calculated for 5-year period
Competitor value market share for insulin as of Aug 2018: Eli Lilly
30% and Sanofi 27%
Competitor value market share for GLP-1 as of Aug 2018: Eli Lilly 41%
and AstraZeneca 13%
OAD: Oral anti-diabetic; MS: Market share
Source: IQVIA MAT Aug, 2018 value figures
2 Percentage change in local currency from YTD Q3 2017 to YTD Q3 2018
3 Comprises Tresiba®, XultophyⓇ and LevemirⓇ; 4 Comprises NovoMix®;
5 Comprises FiaspⓇ and NovoRapid®; 6 Comprises VictozaⓇ and
OzempicⓇ; 7 Comprises NovoNorm® and needles; 8 Comprises primarily
NovoSeven®, NovoEight® NovoThirteen®, Refixia®, Norditropin®,
Vagifem® and Activelle®View entire presentation